LysoPC(14:0/0:0)

Cat. No.: HY-113123

CAS No.: 20559-16-4

Molecular Formula: $C_{22}H_{46}NO_7P$

Molecular Weight: 468

Target: Endogenous Metabolite

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

Ethanol : 50 mg/mL (106.84 mM; Need ultrasonic)

Preparing Stock Solutions

Concentration \ Solvent \ Mass	1 mg	5 mg	10 mg
1 mM	2.1368 mL	10.6838 mL	21.3675 mL
5 mM	0.4274 mL	2.1368 mL	4.2735 mL
10 mM	0.2137 mL	1.0684 mL	2.1368 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. LysoPC(14:0/0:0) has potent antispasmodic effect[1].

IC_{50} & Target

Human Endogenous Metabolite

In Vivo

Of the saturated fatty acid-containing L-α-lysolecithins (LPC), palmitoyl-LPC shows the strongest antispasmodic effect against acetylcholine- or histamine-induced guinea pig ileum contraction; the order of potency of the others is (LysoPC(14:0/0:0)) myristoyl- > stearoyl-, lauroyl- > decanoyl-LPC. Incorporation of a cis-double bond into the C18 fatty acid chain of LPC resulted in a slight decrease of the antispasmodic effect[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tsukatani H, et al.Comparison of antispasmodic effect of synthetic lysolecithins with various fatty acid moieties on guinea pig ileum.J Pharmacobiodyn. 1984 Jun;7(6):400-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA